Drug intelligence / Profile preview

11C-L-deuteriodeprenyl

Development stage
Preclinical
Lead developer
Centro Uruguayo de Imagenología Molecular
Modality
Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

**11C-L-deuteriodeprenyl** is a radiolabeled small molecule used as a positron emission tomography (PET) tracer for in vivo imaging of astrocytosis, particularly in neurodegenerative diseases such as Alzheimer's disease and temporal lobe epilepsy. It is a deuterated analog of L-deprenyl (selegiline), labeled with carbon-11. The compound binds selectively and irreversibly to monoamine oxidase B (MAO-B), an enzyme predominantly located in astrocytes within the brain. By acting as a suicide inhibitor, it forms a covalent bond with MAO-B during normal catalytic activity, allowing visualization of reactive astrocytosis—a process associated with neuronal injury and neurodegeneration—via PET imaging. This tracer has been used to study intermediate processes between amyloid deposition and neuronal loss, providing insights into disease mechanisms and potential monitoring of therapeutic interventions[1][6][8].

Other names
11C-L: -DED
02

Targets

MAOB (Monoamine oxidase B)

Beyond the preview

Go deeper on 11C-L-deuteriodeprenyl.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 11C-L-deuteriodeprenyl.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call